Bright Scistar Biotechnology

Bright Scistar is a clinical-stage biotechnology company focused on developing next-generation Tumor-Infiltrating Lymphocyte (TIL) therapies for solid tumors. Based in Beijing, the company utilizes a proprietary cell expansion platform to produce cryopreserved, autologous TIL products that aim to overcome the limitations of traditional cell therapies. Its lead candidate, BST02, is the first TIL therapy specifically designed for liver cancer to receive IND approval from both the U.S. FDA and China's NMPA. The company's technology focuses on enhancing the potency and scalability of TILs to treat epithelial cancers with high unmet medical needs. Bright Scistar is supported by prominent venture capital firms, including IDG Capital and 5Y Capital, as it advances its pipeline through clinical trials.